Richard Pratley, MD
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1194837476
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Novo Nordisk AS at 27.9% of the total. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $1585.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$205K
- Novo Nordisk$192K
- Lilly USA, LLC$74K
- Merck$64K
- Lexicon Pharmaceuticals, Inc.$46K
- Corcept Therapeutics$41K
- plus $114K from 18 others
Across 971 payments — averaging $8814.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5.7M
- Boehringer Ingelheim International GmbH$2.2M
- Novo Nordisk AS$189K
- Boehringer Ingelheim Pharma GmbH & Co.kg$135K
- AstraZeneca$99K
- Pfizer$71K
- plus $127K from 4 others
What the payments were for
- Consulting fees$376,19451%
- Speaking & faculty fees$220,28430%
- Travel & lodging$127,40317%
- Food & beverage$11,6002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 73 | $205,437 |
| Novo Nordisk | 126 | $192,061 |
| Lilly USA, LLC | 59 | $73,814 |
| Merck | 34 | $63,763 |
| Lexicon Pharmaceuticals, Inc. | 12 | $46,182 |
| Corcept Therapeutics | 43 | $40,683 |
| Boehringer Ingelheim | 29 | $28,755 |
| Pfizer | 21 | $24,529 |
| Amgen | 6 | $12,867 |
| Bayer | 25 | $12,817 |
| AbbVie | 7 | $11,620 |
| F. Hoffmann-la Roche AG | 7 | $10,289 |
| Eli Lilly | 2 | $4,200 |
| Sanofi US Services Inc. | 4 | $2,655 |
| Abbott | 4 | $2,324 |
| Medtronic | 3 | $2,192 |
| Janssen Research & Development, LLC | 1 | $500 |
| Astrazeneca AB | 1 | $450 |
| AstraZeneca | 1 | $100 |
| Zealand Pharma A/s | 1 | $82 |
| Amarin Pharma, Inc. | 1 | $59 |
| Myocardial Solutions, Inc. | 1 | $48 |
| Mannkind Corporation | 1 | $31 |
| Insulet Corporation | 2 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$91,554
- ZEPBOUND$65,909
- Korlym$39,805
- Victoza$26,577
- STEGLATRO$15,822
- Kerendia$9,615
- JARDIANCE$8,590
- Saxenda$6,654
- RYBELSUS$2,338
- MINIMED 780G$2,173
- Tresiba$2,125
- MOUNJARO$2,100
- FreeStyle Libre$1,800
- FREESTYLE LIBRE 3$233
How this compares
$735,481 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $76,643 |
| JardianceEmpagliflozin | 37 | $60,326 |
| MounjaroTirzepatide | 28 | $35,914 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $25,693 |
| TrulicityDulaglutide | 16 | $21,017 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $18,557 |
| FarxigaDapagliflozin Propanediol | 11 | $13,592 |
| InvokanaCanagliflozin | 12 | $8,486 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 17 | $5,080 |
| HumalogInsulin Lispro | 28 | $5,023 |
| SynthroidLevothyroxine Sodium | 21 | $1,811 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 18 | $1,666 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,574 |
| Metformin Hcl | 57 | $495 |
| Glimepiride | 16 | $476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $192,061 | $76,64370 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $73,814 | $61,95472 claims |
| Boehringer IngelheimJardiance | $28,755 | $60,32637 claims |
| AstraZenecaFarxiga | $100 | $13,59211 claims |
| AbbVieSynthroid | $11,620 | $1,81121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Orlando
- Damon TantonOrlando$1.2M
- Hanford YauOrlando$489K
- Steven SmithOrlando$390K
- Tina ThethiOrlando$244K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.